What IQVIA Biotech does

IQVIA Biotech is a full-service Contract Research Organization (CRO) dedicated exclusively to serving biotech and emerging biopharma (EBP) sponsors across all phases of clinical development. Founded in 1998 as PharmaLink (later Novella Clinical), the unit was acquired by Quintiles (now IQVIA Holdings, NYSE: IQV) in 2013 and rebranded as IQVIA Biotech in 2019, operating today as an independent business unit within IQVIA with headquarters in Durham, North Carolina, and a stated global workforce of 10,000+ employees.

The company's offering centers on therapeutic-area–specialized clinical development across oncology, central nervous system (CNS), cardiovascular/renal/metabolic (CVRM), cell and gene therapy (CAGT), dermatology, and internal medicine, supported by dedicated Centers of Excellence (notably the Cell & Gene Therapy Center of Excellence and IQVIA Hematology-Oncology Center of Excellence), a CAGT Study Management Team, decentralized and hybrid trial solutions, and master-protocol and adaptive-design capabilities. Underlying technology is the parent IQVIA's CORE (Connected Intelligence) platform, which combines real-world data, AI/ML analytics, and global site networks across 46+ countries; IQVIA Biotech also leverages Q2 Solutions laboratory services, including CNS biomarker analysis on Quanterix SiMoA instruments.

The business model is professional-services based: custom quote-based, multi-year enterprise contracts with biotech and EBP sponsors, sold via direct enterprise field sales and strategic account management. The unit serves a long tail of small-to-mid-cap biotech sponsors; documented scale signals include 1,000+ CNS trials over 10 years, 500+ CVRM studies over 5 years, 200+ full-service CAGT trials over 5 years, and 300+ rare disease studies. Geographic reach spans North America, Europe, JAPAC (15 countries via a Tokyo-based regional HQ), Latin America, and Middle East/Africa. No standalone revenue is disclosed; IQVIA Biotech reports through its parent IQVIA Holdings.

Name

IQVIA Biotech

Legal name

IQVIA Biotech

Website

https://iqviabiotech.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

IQVIA Biotech is a full-service CRO exclusively serving biotech and emerging biopharma sponsors across all trial phases, with therapeutic specialization in oncology, CNS, CVRM, cell & gene therapy, dermatology, and internal medicine, delivered via a 10,000+ employee global organization headquartered in Durham, NC.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Clinical Development Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Biotech clinical trials
• Contract research services
• Cell gene therapy trials
• Oncology clinical development
• Emerging biopharma CRO

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Development Services: Full-service CRO services for biotech and emerging biopharma companies across all phases of drug development and therapeutic areas. Services include clinical operations, project management, regulatory affairs, data management, and therapeutic expertise.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

IQVIA Biotech is a full-service contract research organization (CRO) that provides clinical development solutions exclusively for biotech and emerging biopharma companies. Its offerings span clinical operations, project management, regulatory affairs, biostatistics, data management, medical monitoring, real-world evidence generation, and therapeutic-area expertise across oncology, CNS, CVRM, cell and gene therapy, dermatology, and internal medicine, all phases of drug development, leveraging IQVIA's Connected Intelligence platform, global site networks, and decentralized trial technologies.

Product overview

IQVIA Biotech is a specialized full-service Contract Research Organization (CRO) dedicated exclusively to serving biotech and emerging biopharma companies. The offering consists of a unified clinical development platform with therapeutic expertise across Oncology, CNS, CVRM, Cell & Gene Therapy, Dermatology, and Internal Medicine. Core services include Clinical Development Solutions, Real World Evidence generation, and Connected Intelligence technology platform. The portfolio includes dedicated therapeutic service lines paired with Centers of Excellence (Cell & Gene Therapy, CNS) and specialized teams (CAGT Study Management Team) that integrate with IQVIA Biotech's clinical program strategy. Additional offerings include Decentralized and Hybrid trial solutions, master protocol trial design, and global site networks. The company supports all phases of clinical development from early phase through regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Solutions Full-service clinical development with specialized, dedicated teams for biotech and emerging biopharma sponsors across all phases and therapeutic areas, delivered through IQVIA Biotech's project management, clinical operations, regulatory, data management, and biostatistics capabilities.
• Oncology Clinical Trials Specialized oncology clinical trial solutions for biotech and emerging biopharma sponsors, leveraging IQVIA Biotech's Hematology-Oncology Center of Excellence to accelerate breakthroughs across solid tumor and hematologic malignancy drug development.
• Central Nervous System (CNS) Clinical Trials CNS clinical trial services for biotech sponsors targeting neurological indications including Alzheimer's, Parkinson's, and rare neurological diseases, supported by IQVIA's global CNS key opinion leader and site networks and 1,000+ prior CNS clinical trials.
• Cardiovascular, Renal & Metabolic (CVRM) Clinical Trials Clinical development services for cardiovascular, renal, and metabolic therapies, addressing comorbidities such as obesity, diabetes, and chronic kidney disease across more than 500 CVRM studies completed in the past 5 years.
• Cell & Gene Therapy (CAGT) Clinical Trials Pioneering clinical trial solutions for cell and gene therapies, including CAR-T programs, with dedicated multidisciplinary CAGT Study Management teams and the Cell & Gene Therapy Center of Excellence covering regulatory navigation, manufacturing logistics, and site activation; 200+ full-service CAGT trials supported over the past 5 years.
• Dermatology Clinical Trials Tailored dermatology clinical trial approaches with board-certified dermatologists on staff, supporting biotech innovation across all phases including moderate-to-severe dermatology indications such as hidradenitis suppurativa.
• Internal Medicine Clinical Trials Specialized internal medicine trial services covering subspecialties including gastroenterology, hepatology, immunology, infectious disease, ophthalmology, rare disease, respiratory, rheumatology, and vaccines.
• Cell & Gene Therapy Center of Excellence Integrated center of excellence providing therapeutic, regulatory, and operational expertise for cell and gene therapy clinical trials, leveraging standardized platform-based approaches and the Bespoke Gene Therapy Consortium's regulatory playbook to streamline development for rare diseases and CAGT programs.
• Real World Evidence Real-world evidence generation and dissemination service for biotech sponsors, leveraging IQVIA's data resources, predictive analytics, and machine learning to track diagnosis and treatment patterns in real-world settings.

Quantifiable outcome

• Met enrollment targets two weeks early during COVID-19 pandemic using innovative recruitment strategies
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development Partner · 1 October 2023IQVIA and CEPI collaboration to strengthen global research preparedness and advance the 100 Days Mission, supporting faster vaccine and therapeutic development for pandemic threats.
• Bespoke Gene Therapy Consortium (BGTC)coreStrategic or Co-development PartnerIQVIA leverages the BGTC's regulatory playbook as a guiding framework to expedite delivery of therapies to patients. Collaborating with industry and nonprofit partners to develop standardized platform-based approaches and streamline regulatory navigation for rare diseases and cell and gene therapies.
• TRICALSminorStrategic or Co-development PartnerCollaborative partnership focused on advancing clinical trials for ALS (Amyotrophic Lateral Sclerosis) research, supporting the neurodegenerative disease community.
• Q2 SolutionscoreTechnology or IntegrationIQVIA Biotech leverages Q2 Solutions laboratory services for biomarker analysis, including CNS biomarkers (Aβ40/42, Tau/pTau, NfL) using high sensitivity immunoassay instruments like Quanterix SiMoA for plasma biomarker testing in clinical trials.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Parexel International: Large global CRO with significant biotech and emerging biopharma exposure and strong therapeutic-area franchises in oncology and rare disease. Comparable full-service clinical development offerings across all phases.
• Thermo Fisher Scientific (PPD): Through its PPD clinical research services business, Thermo Fisher offers global full-service CRO capabilities including biotech and emerging biopharma programs. Competes across therapeutic areas with the scale of a major life-sciences conglomerate.
• Syneos Health: Now-private global biopharma solutions organization offering full-service clinical development alongside commercial services. Overlaps with IQVIA Biotech on biotech-sponsored trials while offering a broader clinical-to-commercial model.
• ICON plc: One of the largest global CROs offering full-service clinical development across all major therapeutic areas. Competes with IQVIA Biotech for biotech and large pharma sponsors but is a broad incumbent rather than biotech-exclusive.
• Labcorp Drug Development (formerly Covance): Large clinical development and central laboratory services provider serving both biotech and large pharma. Comparable end-to-end clinical offering with central lab capabilities analogous to Q2 Solutions.

Direct peers

• Medpace Holdings: Mid-to-large full-service CRO with a strong focus on emerging and mid-sized biotech sponsors across multiple therapeutic areas. Comparable business model of dedicated biotech client service, project-based pricing, and similar therapeutic-area breadth.
• Premier Research: Specialty CRO focused on small and mid-sized biotech with therapeutic expertise in oncology, rare disease, CNS, and cell & gene therapy. Direct overlap with IQVIA Biotech's EBP-centric model and therapeutic portfolio.
• Worldwide Clinical Trials: Mid-sized CRO purpose-built for biotech and emerging biopharma with therapeutic depth in CNS, oncology, and rare disease. Closely matches IQVIA Biotech's EBP-exclusive positioning and therapeutic-area mix.
• Charles River Laboratories: Provides preclinical and clinical research services to biotech sponsors, with growing cell and gene therapy capabilities through its CDMO and biologics services. Adjacent overlap on biotech/EBP client base and CAGT focus.

Regional players

• WuXi AppTec / WuXi Clinical: Asia-headquartered CRO/CDMO with global clinical development capabilities, particularly strong with Chinese and APAC biotech sponsors. Competes for biotech trial work, especially in JAPAC, but with a different regional anchor than IQVIA Biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/showcase/iqvia-biotech
• Xx.com/IQVIA_Biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IQVIA Biotech